NEW YORK, Sept. 27, 2022 /PRNewswire/ — Mind Medicine (MindMed) Inc. (“MindMed”) ( Nasdaq: MNMD) (NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it intends to offer and sell, subject to market conditions, common shares with accompanying warrants to purchase common shares in an underwritten public offering.


Previous articleBetterLife Files Comprehensive Patent for BETR-001 and Other LSD Derivatives
Next articleSilo Pharma Announces Uplisting to Nasdaq Capital Market and Pricing of $5 Million Public Offering of Common Stock